Goldman Sachs initiated coverage of Iovance Biotherapeutics with a Buy rating and $12 price target. The company is developing autologous tumor-infiltrating lymphocyte therapies for solid tumor cancers with lead asset lifileucel under regulatory review, the analyst tells investors in a research note. The firm says the upcoming approval of the first TIL therapy will transition Iovance to a commercial company and it is constructive on the near- and long-term launch potential given lifileucel’s “best-in-class” profile and early signs of key opinion leader enthusiasm.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on IOVA:
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
- Iovance Biotherapeutics price target lowered to $28 from $38 at H.C. Wainwright
- Iovance Biotherapeutics reports Q3 EPS 46c, consensus 45c
- Iovance Biotherapeutics Reports Third Quarter and Year-to-Date 2023 Financial Results and Corporate Updates
- Iovance Biotherapeutics options imply 10.1% move in share price post-earnings